Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

Impact of minimal residual disease outcomes with ciltacabtagene autoleucel in cartitude-4: Oncologist treatment preferences in lenalidomide-refractory multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

SCSolly ChedidMBMuhamed Baljević

Discussion

Loading...

Member takes

Overview

Observational analysis identified 88% of U.S. oncologists preferred CAR T therapy, indicating clinical significance of MRD in treatment decisions.

Key Points

  • Ciltacabtagene autoleucel significantly improved treatment preferences for lenalidomide-refractory multiple myeloma with the latest data.
  • Prior to reviewing data, only 63% preferred CAR T therapy; after, this increased to 88% among oncologists surveyed.
  • Surveys revealed key influences on clinical decision-making included patient fitness and disease aggressiveness for MRD assessment.
  • Identifying barriers such as CAR T center capacity emphasizes the need for accessible treatment options in modern oncology.

Cite This Study

Chedid et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d9c7https://doi.org/10.1182/blood-2025-4572
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Long-term progression-free survival benefit with ciltacabtagene autoleucel in standard-risk relapsed / refractory multiple myeloma2025 · 4 citations
  2. 2Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician’s Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma2025 · 3 citations
  3. 3CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.2023 · 117 citations
  4. 4Bridging therapy response and low pre-lymphodepletion plasma cell burden are associated with improved safety and efficacy outcomes of ciltacabtagene autoleucel in multiple myeloma2025 · 5 citations
  5. 5The efficacy of cilta-cel after a prior BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma2025 · 2 citations